| Comprehensive molecular profiling of lung adenocarcinoma Cancer Genome Atlas Research Network Nature 511 (7511), 543, 2014 | 4940* | 2014 |
| The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma A Rosenwald, G Wright, WC Chan, JM Connors, E Campo, RI Fisher, ... New England Journal of Medicine 346 (25), 1937-1947, 2002 | 4878 | 2002 |
| Comprehensive genomic characterization of squamous cell lung cancers Cancer Genome Atlas Research Network Nature 489 (7417), 519, 2012 | 3839 | 2012 |
| Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin KA Hoadley, C Yau, DM Wolf, AD Cherniack, D Tamborero, S Ng, ... Cell 158 (4), 929-944, 2014 | 1608 | 2014 |
| Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas JD Campbell, A Alexandrov, J Kim, J Wala, AH Berger, CS Pedamallu, ... Nature genetics 48 (6), 607-616, 2016 | 1225 | 2016 |
| The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma A Rosenwald, G Wright, A Wiestner, WC Chan, JM Connors, E Campo, ... Cancer cell 3 (2), 185-197, 2003 | 1099 | 2003 |
| An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor … LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ... Clinical cancer research 19 (1), 279-290, 2013 | 1066 | 2013 |
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ... Nature Reviews Cancer 19 (5), 289-297, 2019 | 1040 | 2019 |
| Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression L Chen, DL Gibbons, S Goswami, MA Cortez, YH Ahn, LA Byers, X Zhang, ... Nature communications 5 (1), 5241, 2014 | 978 | 2014 |
| Comprehensive and integrated genomic characterization of adult soft tissue sarcomas AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ... Cell 171 (4), 950-965, 2017 | 921 | 2017 |
| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 861 | 2015 |
| Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer T Sen, BL Rodriguez, L Chen, CMD Corte, N Morikawa, J Fujimoto, ... Cancer discovery 9 (5), 646-661, 2019 | 726 | 2019 |
| Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities CM Gay, CA Stewart, EM Park, L Diao, SM Groves, S Heeke, BY Nabet, ... Cancer cell 39 (3), 346-360. e7, 2021 | 715 | 2021 |
| Small cell lung cancer: where do we go from here? LA Byers, CM Rudin Cancer 121 (5), 664-672, 2015 | 691 | 2015 |
| Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome NT Ihle, LA Byers, ES Kim, P Saintigny, JJ Lee, GR Blumenschein, A Tsao, ... Journal of the National Cancer Institute 104 (3), 228-239, 2012 | 607 | 2012 |
| A pan-cancer proteomic perspective on The Cancer Genome Atlas R Akbani, PKS Ng, HMJ Werner, M Shahmoradgoli, F Zhang, Z Ju, W Liu, ... Nature communications 5 (1), 3887, 2014 | 591 | 2014 |
| Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1 LA Byers, J Wang, MB Nilsson, J Fujimoto, P Saintigny, J Yordy, U Giri, ... Cancer discovery 2 (9), 798-811, 2012 | 570 | 2012 |
| Integrative molecular characterization of malignant pleural mesothelioma J Hmeljak, F Sanchez-Vega, KA Hoadley, J Shih, C Stewart, D Heiman, ... Cancer discovery 8 (12), 1548-1565, 2018 | 566 | 2018 |
| Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study CM Rudin, MC Pietanza, TM Bauer, N Ready, D Morgensztern, ... The Lancet Oncology 18 (1), 42-51, 2017 | 554 | 2017 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 533 | 2021 |